NOVAVAX INC Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate
NOVAVAX INC (NVAX) reported Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate of 1.19% for the 3-month period ending 2015-03-31, per its 10-Q filed 2016-05-05.
Discontinued › Notes › Compensation Related Costs › Share-Based Payment Arrangement, Disclosure › Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions and Methodology
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate · last filed 2016-05-05
- NOVAVAX INC share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate for the quarter ending 2015-03-31 was 1.19%.
- NOVAVAX INC share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate for the quarter ending 2012-09-30 was 0.55%.
- NOVAVAX INC share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate for the quarter ending 2012-06-30 was 0.59%.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate 3 month |
|---|---|
| 2015-03-31 | 1.19% 10-Q · filed 2016-05-05 |
| 2012-09-30 | 0.55% 10-Q · filed 2013-11-12 |
| 2012-06-30 | 0.59% 10-Q · filed 2013-08-08 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Vir Biotechnology, Inc. (VIR) | United States | $1.814B | -6.85 |
| Hemab Therapeutics Holdings, Inc. (COAG) | United States | $1.672B | |
| Immunocore Holdings plc (IMCR) | $1.613B | -90.43 | |
| Taysha Gene Therapies, Inc. (TSHA) | United States | $1.564B | -14.80 |
| Vericel Corp (VCEL) | United States | $2.011B | 93.97 |
| Inhibrx Biosciences, Inc. (INBX) | United States | $1.477B | -10.08 |
| Maze Therapeutics, Inc. (MAZE) | United States | $1.457B | -12.40 |
| RECURSION PHARMACEUTICALS, INC. (RXRX) | United States | $2.080B | -3.78 |
| Kodiak Sciences Inc. (KOD) | United States | $2.090B | -10.12 |
| ADMA BIOLOGICS, INC. (ADMA) | United States | $2.131B | 11.16 |